 Connection
James Cooper to Graft Survival
This is a "connection" page, showing publications James Cooper has written about Graft Survival.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.091 |
|
|
|
-
Cooper JE. Evaluation and Treatment of Acute Rejection in Kidney Allografts. Clin J Am Soc Nephrol. 2020 03 06; 15(3):430-438.
Score: 0.582
-
Davis S, Gralla J, Klem P, Tong S, Wedermyer G, Freed B, Wiseman A, Cooper JE. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am J Transplant. 2018 04; 18(4):907-915.
Score: 0.496
-
Cooper JE, Gralla J, Klem P, Chan L, Wiseman AC. High dose intravenous immunoglobulin therapy for donor-specific antibodies in kidney transplant recipients with acute and chronic graft dysfunction. Transplantation. 2014 Jun 27; 97(12):1253-9.
Score: 0.394
-
Cooper JE, Gralla J, Adebiyi O, Wiseman AC, Chan L. Donor specific antibodies before and after kidney transplant: the University of Colorado Experience. Clin Transpl. 2013; 407-12.
Score: 0.355
-
Cooper JE, Gralla J, Cagle L, Goldberg R, Chan L, Wiseman AC. Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation. 2011 May 27; 91(10):1103-9.
Score: 0.318
-
Cooper JE, Wiseman AC, Chan L. Bortezomib use in chronic antibody-mediated allograft dysfunction: updates and additional cases. Clin Transpl. 2010; 415-20.
Score: 0.289
-
Davis S, Wiebe C, Campbell K, Anobile C, Aubrey M, Stites E, Grafals M, Pomfret E, Nickerson P, Cooper JE. Adequate tacrolimus exposure modulates the impact of HLA class II molecular mismatch: a validation study in an American cohort. Am J Transplant. 2021 01; 21(1):322-328.
Score: 0.152
-
Davis S, Gralla J, Klem P, Stites E, Wiseman A, Cooper JE. Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies. Transplantation. 2020 04; 104(4):881-887.
Score: 0.147
-
Mithani Z, Gralla J, Adebiyi O, Klem P, Cooper JE, Wiseman AC. De Novo Donor-Specific Antibody Formation in Tacrolimus-Based, Mycophenolate Versus Mammalian Target of Rapamycin Immunosuppressive Regimens. Exp Clin Transplant. 2018 02; 16(1):23-30.
Score: 0.119
-
Alfonso J, Gralla J, Klem P, Chan L, Wiseman AC, Cooper JE. High-Dose Intravenous Immunoglobulin Therapy for Donor Specific Antibodies in Kidney Transplant Recipients with Acute and Chronic Graft Dysfunction: Updates on Previously Reported Cohorts. Clin Transpl. 2014; 161-70.
Score: 0.095
-
Cooper JE, Gralla J, Chan L, Wiseman AC. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Clin Transpl. 2011; 359-64.
Score: 0.077
-
Weir MR, Burgess ED, Cooper JE, Fenves AZ, Goldsmith D, McKay D, Mehrotra A, Mitsnefes MM, Sica DA, Taler SJ. Assessment and management of hypertension in transplant patients. J Am Soc Nephrol. 2015 Jun; 26(6):1248-60.
Score: 0.026
-
Gralla J, Le CN, Cooper JE, Wiseman AC. The risk of acute rejection and the influence of induction agents in lower-risk African American kidney transplant recipients receiving modern immunosuppression. Clin Transplant. 2014 Mar; 28(3):292-8.
Score: 0.024
-
Klem P, Cooper JE, Weiss AS, Gralla J, Owen P, Chan L, Wiseman AC. Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients. Transplantation. 2009 Oct 15; 88(7):891-6.
Score: 0.018
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|